| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CNTX Stock Overview
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States.
Context Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.96 |
| 52 Week High | US$10.87 |
| 52 Week Low | US$1.27 |
| Beta | 0 |
| 1 Month Change | 2.08% |
| 3 Month Change | 35.17% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -61.57% |
Recent News & Updates
Context Therapeutics GAAP EPS of -$0.25 in-line
Context Therapeutics press release (NASDAQ:CNTX): Q2 GAAP EPS of -$0.25 in-line. Cash, cash equivalents, and restricted cash were $42.9 million.
Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trial
Context Therapeutics (NASDAQ:CNTX) and Italian pharmaceutical major Menarini Group have entered into a clinical trial collaboration and supply agreement to evaluate a breast cancer combination treatment, the companies said on Tuesday. The agreement will support the upcoming phase 1b/2 ELONA clinical trial evaluating CNTX's oral progesterone receptor (PR) antagonist ONA-XR in combination with Menarini's elacestrant in estrogen receptor positive, PR+ HER2- metastatic breast cancer patients who have previously been treated with a CDK4/6 inhibitor. Context (CNTX) will sponsor the trial while Menarini will supply elacestrant at no cost. CNTX said it anticipates starting the phase 1b/2 trial in Q4 this year. CNTX stock gained 5.8% to $2 in premarket trading.
Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Shareholder Returns
| CNTX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.1% | 1.1% | 3.2% |
| 1Y | n/a | 1.3% | -10.2% |
Return vs Industry: Insufficient data to determine how CNTX performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CNTX performed against the US Market.
Price Volatility
| CNTX volatility | |
|---|---|
| CNTX Average Weekly Movement | 11.8% |
| Pharmaceuticals Industry Average Movement | 11.8% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CNTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: CNTX's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 2 | Martin Lehr | https://www.contexttherapeutics.com |
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Context Therapeutics Inc. Fundamentals Summary
| CNTX fundamental statistics | |
|---|---|
| Market Cap | US$31.29m |
| Earnings (TTM) | -US$11.96m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.6x
P/E RatioIs CNTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$11.96m |
| Earnings | -US$11.96m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.75 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CNTX perform over the long term?
See historical performance and comparison